Cabaletta Bio’s Strong Financial Position and Strategic Clinical Progress Justify Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on CABA stock, giving a Buy rating today.

Phil Nadeau has given his Buy rating due to a combination of factors including Cabaletta Bio’s strong financial position and strategic progress in clinical trials. The company had $132 million in cash as of March 31, which provides a financial runway into the first half of 2026, indicating a stable financial foundation to support ongoing and future operations.
Furthermore, Cabaletta Bio has achieved alignment with the FDA on the design of pivotal trials for rese-cel in myositis, with plans to enroll two cohorts of 15 patients each. The FDA’s support for a pooled safety dataset and the expectation that a database of approximately 100 patients with over a month of follow-up is sufficient for approval, underscores the potential for successful trial outcomes. Additionally, Cabaletta’s plans to expand the current RESET trial and the anticipated BLA submission in 2027 further solidify the company’s strategic positioning and potential for growth, justifying the Buy rating.

According to TipRanks, Nadeau is a 2-star analyst with an average return of 0.1% and a 37.92% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Neurocrine, and Voyager Therapeutics.